Germantown, Md.-based Senseonics Holdings Inc. (NYSE-MKT:SENS) is touting positive results from a study of its Eversense implantable continuous glucose monitoring (CGM) system, reporting that the technology demonstrated "strong accuracy" over 90 days of uninterrupted wear. The news comes as the CGM arena heats up, with Dublin-based Medtronic plc, San Diego-based Dexcom Inc., and others looking to make a splash.